The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer

References

• FerlayJ, SoerjomataramI, DikshitR, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–386. doi:10.1002/ijc.2921025220842
   PubMed Web of Science ®Google Scholar
• BabjukM, BurgerM, CompératEM, et al. European Association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol. 2019;76(5):639–657. doi:10.1016/j.eururo.2019.08.01631443960
   PubMed Web of Science ®Google Scholar
• ProutGRJr, BartonBA, GriffinPP, FriedellGH; The National Bladder Cancer Group. Treated history of noninvasive grade 1 transitional cell carcinoma. J Urol. 1992;148(5):1413–1419. doi:10.1016/S0022-5347(17)36924-01433540
   PubMed Web of Science ®Google Scholar
• HongYM, LoughlinKR. Economic impact of tumor markers in bladder cancer surveillance. Urology. 2008;71(1):131–135. doi:10.1016/j.urology.2007.08.01418242381
   PubMed Web of Science ®Google Scholar
• WołącewiczM, HrynkiewiczR, GrywalskaE. Immunotherapy in bladder cancer: current methods and future perspectives. Cancers. 2020;12(5):1181. doi:10.3390/cancers12051181
   PubMed Web of Science ®Google Scholar
• LoriotY, NecchiA, ParkSH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. 2019;381(4):338–348. doi:10.1056/NEJMoa181732331340094
   PubMed Web of Science ®Google Scholar
• ShahinO, ThalmannGN, RentschC, MazzucchelliL, StuderUE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol. 2003;169(1):96–100; discussion 100. doi:10.1016/S0022-5347(05)64044-X12478112
   PubMed Web of Science ®Google Scholar
• BabjukM, BohleA, BurgerM, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–461. doi:10.1016/j.eururo.2016.05.041
   Web of Science ®Google Scholar
• KnowlesMA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol. 2008;4(1):71–83. doi:10.2217/14796694.4.1.7118241002
   PubMed Web of Science ®Google Scholar
• KnowlesMA. FGFR3 – a central player in bladder cancer pathogenesis?Bladder Cancer. 2020;Preprint:1–21.
   Google Scholar
• HernándezS, López-KnowlesE, LloretaJ, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24(22):3664–3671. doi:10.1200/JCO.2005.05.177116877735
   PubMed Web of Science ®Google Scholar
• van RhijnBW, ZuiverloonTC, VisAN, et al. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol. 2010;58(3):433–441. doi:10.1016/j.eururo.2010.05.04320646825
   PubMed Web of Science ®Google Scholar
• BurgerM, van der AaMN, van OersJM, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a Prospective Study. Eur Urol. 2008;54(4):835–843. doi:10.1016/j.eururo.2007.12.02618166262
   PubMed Web of Science ®Google Scholar
• Gómez-RománJJ, SaenzP, MolinaM, et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res. 2005;11(2 Pt 1):459–465.15701828
   PubMed Web of Science ®Google Scholar
• Mhawech-FaucegliaP, CheneyRT, FischerG, BeckA, HerrmannFR. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 2006;32(2):231–237. doi:10.1016/j.ejso.2005.11.01816412606
   PubMed Web of Science ®Google Scholar
• TomlinsonDC, BaldoO, HarndenP, KnowlesMA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213(1):91–98. doi:10.1002/path.220717668422
   PubMed Web of Science ®Google Scholar
• van RhijnBW, LurkinI, RadvanyiF, KirkelsWJ, van der KwastTH, ZwarthoffEC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61(4):1265–1268.11245416
   PubMed Web of Science ®Google Scholar
• HernándezS, López-KnowlesE, LloretaJ, et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res. 2005;11(15):5444–5450. doi:10.1158/1078-0432.CCR-05-012216061860
   PubMed Web of Science ®Google Scholar
• RichterJ, JiangF, GörögJP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997;57(14):2860–2864.9230190
   PubMed Web of Science ®Google Scholar
• BreyerJ, WirtzRM, ErbenP, et al. High CDKN2A/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma. Clin Genitourin Cancer. 2018;16(4):248–256.e242. doi:10.1016/j.clgc.2018.01.00929525349
   PubMed Web of Science ®Google Scholar
• PollardC, SmithSC, TheodorescuD. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med. 2010;12:e10. doi:10.1017/S146239941000140720334706
   PubMed Web of Science ®Google Scholar
• BerggrenP, KumarR, SakanoS, et al. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res. 2003;9(1):235–242.12538475
   PubMed Web of Science ®Google Scholar
• AbatD, DemirhanO, InandikliogluN, et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett. 2014;8(1):25–32. doi:10.3892/ol.2014.210824959214
   PubMed Web of Science ®Google Scholar
• PloussardG, SolimanH, DubosqF, et al. The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22. Am J Cancer Res. 2011;1(4):498–507.21984968
   PubMed Web of Science ®Google Scholar
• BreyerJ, WirtzRM, OttoW, et al. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Arch. 2017;470(3):267–274. doi:10.1007/s00428-017-2064-828074276
   PubMed Web of Science ®Google Scholar
• EcksteinM, WirtzRM, Gross-WeegeM, et al. mRNA-expression of KRT5 and KRT20 defines distinct prognostic subgroups of muscle-invasive urothelial bladder cancer correlating with histological variants. Int J Mol Sci. 2018;19(11):11. doi:10.3390/ijms19113396
   Web of Science ®Google Scholar
• van RhijnBW, BurgerM. Bladder cancer: low adherence to guidelines in non-muscle-invasive disease. Nat Rev Urol. 2016;13(10):570–571. doi:10.1038/nrurol.2016.16527578042
   PubMed Web of Science ®Google Scholar
• IedaT, MutoS, ShimizuF, et al. Development and validation of a novel recurrence risk stratification for initial non-muscle invasive bladder cancer in Asia. EBioMedicine. 2016;12:98–104. doi:10.1016/j.ebiom.2016.08.05127614395
   PubMed Web of Science ®Google Scholar
• GerdesJ, SchwabU, LemkeH, SteinH. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31(1):13–20. doi:10.1002/ijc.29103101046339421
   PubMed Web of Science ®Google Scholar
• van RhijnBW, van der KwastTH, VisAN, et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;64(6):1911–1914. doi:10.1158/0008-5472.CAN-03-242115026322
   PubMed Web of Science ®Google Scholar
• van OersJM, ZwarthoffEC, RehmanI, et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650–657. doi:10.1016/j.eururo.2008.06.01318584939
   PubMed Web of Science ®Google Scholar
• Di MartinoE, TomlinsonDC, KnowlesMA. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol. 2012;2012(429213):1–10. doi:10.1155/2012/429213
   Google Scholar
• HosenI, RachakondaPS, HeidenreichB, et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer. 2015;137(7):1621–1629. doi:10.1002/ijc.2952625809917
   PubMed Web of Science ®Google Scholar
• ZiegerK, DyrskjøtL, WiufC, et al. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors. Clin Cancer Res. 2005;11(21):7709–7719. doi:10.1158/1078-0432.CCR-05-113016278391
   PubMed Web of Science ®Google Scholar
• KimSJ, NamW, YouD, et al. Prognostic factors related to recurrence-free survival for primary carcinoma in situ of the bladder after bacillus calmette-guérin: a Retrospective Study. Urol Int. 2018;101(3):269–276. doi:10.1159/00049212130179882
   PubMed Web of Science ®Google Scholar
• Kardoust PariziM, MargulisV, LotanY, MoriK, ShariatSF. Fibroblast growth factor receptor: a systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. Urol Oncol. 2021;39(7):409–421. doi:10.1016/j.urolonc.2021.01.02533642228
   PubMed Web of Science ®Google Scholar
• VeltmanJA, FridlyandJ, PejavarS, et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res. 2003;63(11):2872–2880.12782593
   PubMed Web of Science ®Google Scholar
• BartolettiR, CaiT, NesiG, Roberta GirardiL, BaroniG, Dal CantoM. Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res. 2007;143(2):422–427. doi:10.1016/j.jss.2007.01.01217612565
   PubMed Web of Science ®Google Scholar
• RebouissouS, HéraultA, LetouzéE, et al. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma. J Pathol. 2012;227(3):315–324. doi:10.1002/path.401722422578
   PubMed Web of Science ®Google Scholar
• DownesMR, WeeningB, van RhijnBW, HaveCL, TreurnietKM, van der KwastTH. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway. Histopathology. 2017;70(2):281–289. doi:10.1111/his.1306327530957
   PubMed Web of Science ®Google Scholar
• WorstTS, WeisCA, StöhrR, et al. CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Sci Rep. 2018;8(1):14383.30258198
   PubMed Web of Science ®Google Scholar
• ShariatSF, TokunagaH, ZhouJ, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014–1024. doi:10.1200/JCO.2004.03.11814981102
   PubMed Web of Science ®Google Scholar
• LindgrenD, FrigyesiA, GudjonssonS, et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 2010;70(9):3463–3472. doi:10.1158/0008-5472.CAN-09-421320406976
   PubMed Web of Science ®Google Scholar
• VogelsteinB, PapadopoulosN, VelculescuVE, ZhouS, DiazLAJr, KinzlerKW. Cancer genome landscapes. Science. 2013;339(6127):1546–1558. doi:10.1126/science.123512223539594
   PubMed Web of Science ®Google Scholar
• LukasJ, ParryD, AagaardL, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature. 1995;375(6531):503–506. doi:10.1038/375503a07777060
   PubMed Web of Science ®Google Scholar
• PomerantzJ, Schreiber-AgusN, LiégeoisNJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell. 1998;92(6):713–723. doi:10.1016/S0092-8674(00)81400-29529248
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–322. doi:10.1038/nature1296524476821
   PubMed Web of Science ®Google Scholar
• MeeksJJ, CarneiroBA, PaiSG, et al. Genomic characterization of high-risk non-muscle invasive bladder cancer. Oncotarget. 2016;7(46):75176–75184. doi:10.18632/oncotarget.1266127750214
   PubMedGoogle Scholar
• HedegaardJ, LamyP, NordentoftI, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30(1):27–42. doi:10.1016/j.ccell.2016.05.00427321955
   PubMed Web of Science ®Google Scholar
• Al-KhalafHH, ColakD, Al-SaifM, et al. p16(INK4a) positively regulates cyclin D1 and E2F1 through negative control of AUF1. PLoS One. 2011;6(7):e21111. doi:10.1371/journal.pone.002111121799732
   PubMed Web of Science ®Google Scholar
• OverhoffMG, GarbeJC, KohJ, StampferMR, BeachDH, BishopCL. Cellular senescence mediated by p16INK4A-coupled miRNA pathways. Nucleic Acids Res. 2014;42(3):1606–1618. doi:10.1093/nar/gkt109624217920
   PubMed Web of Science ®Google Scholar
• SjödahlG, LaussM, LövgrenK, et al. A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 2012;18(12):3377–3386. doi:10.1158/1078-0432.CCR-12-0077-T22553347
   PubMed Web of Science ®Google Scholar
• HurstCD, KnowlesMA. Bladder cancer: multi-omic profiling refines the molecular view. Nat Rev Clin Oncol. 2018;15(4):203–204. doi:10.1038/nrclinonc.2017.19529255240
   PubMed Web of Science ®Google Scholar
• HahnNM, BivalacquaTJ, RossAE, et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier cancer research network trial HCRN 12-157. Clin Cancer Res. 2017;23(12):3003–3011. doi:10.1158/1078-0432.CCR-16-226727932416
   PubMed Web of Science ®Google Scholar
• AfferiL, MoschiniM, CumberbatchMG, et al.; European Association of Urology - European Society of Resident Urologists (EAU-ESRU). Biomarkers predicting oncological outcomes of high-risk non-muscle-invasive bladder cancer. Minerva Urol Nefrol. 2020;72(3):265–278. doi:10.23736/S0393-2249.20.03786-832298067
   PubMed Web of Science ®Google Scholar
• KangHW, KimYH, JeongP, et al. Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncol Lett. 2017;14(3):3817–3824. doi:10.3892/ol.2017.662128927152
   PubMed Web of Science ®Google Scholar
• EcksteinM, WirtzRM, PfannstilC, et al. A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget. 2018;9(19):15001–15014. doi:10.18632/oncotarget.2453129599921
   PubMedGoogle Scholar